Home›Valproic Acid›Valproic Acid + Nimodipine

Does Valproic Acid Interact with Nimodipine?

CDI records a moderate classification for Valproic Acid and Nimodipine. The stored summary is: Moderate CYP3A4 inhibitor that may increase nimodipine plasma concentration and blood pressure lowering effect. Blood pressure monitoring and dose reduction of nimodipine may be necessary. The mechanism involves cyp3a4 inhibition may increase nimodipine plasma concentration. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Saved label reference on DailyMed. This identifier has not been checked here as support for the current claim.

Stored CDI classification
Moderate
Valproic Acid Class
Anti-epileptic Agent
Nimodipine Class
Dihydropyridine Calcium Channel Blocker
Management
Confirm exact products with your pharmacist
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

CYP3A4 inhibition may increase nimodipine plasma concentration

What To Tell Your Doctor or Pharmacist

If you are taking Valproic Acid and your doctor is considering prescribing Nimodipine (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Valproic Acid(Valproic Acid)+💊 Nimodipine(Nymalize)

Severity & Interaction Details

🟡
moderate
Stored CDI classification: moderate
A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.
Severity scale
MinorContra
On record
Yes
Drug A class
Anti-epileptic Agent
Drug B class
Dihydropyridine Calcium Channel Blocker
Source
NLP:nimodipine

What this means in plain English

Moderate CYP3A4 inhibitor that may increase nimodipine plasma concentration and blood pressure lowering effect. Blood pressure monitoring and dose reduction of nimodipine may be necessary.

About Valproic Acid and Nimodipine

Valproic Acid is an Anti-epileptic Agent, while Nimodipine is a Dihydropyridine Calcium Channel Blocker. Nimodipine is also sold under the brand name Nymalize. Both Valproic Acid and Nimodipine carry an FDA boxed warning — the agency's most serious safety designation.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:nimodipine

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Valproic Acid and Nimodipine against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations